Showing 3441-3450 of 4062 results for "".
- Ultrasound Gave Us Our First Baby Pictures. Can It Also Help the Blind See?https://modernod.com/news/ultrasound-gave-us-our-first-baby-pictures-can-it-also-help-the-blind-see/2480771/The number of Americans with visual impairment or blindness is expected to jump to more than 8 million by the year 2050,
- Zeiss to Unveil Clinical Insights Supporting the Value of New Data-Driven Digital Workflow Solutions and Software Applicationshttps://modernod.com/news/zeiss-to-unveil-clinical-insights-supporting-the-value-of-new-data-driven-digital-workflow-solutions-and-software-applications/2480752/Zeiss Medical Technology will host ZEISS Innovation Day on April 7, 2022, showcasing clinical perspectives from global experts with first-hand experience integrating devices, data and software applications.
- Nova Eye President Appointed to American Glaucoma Society (AGS) Foundation Advisory Boardhttps://modernod.com/news/nova-eye-president-appointed-to-american-glaucoma-society-ags-foundation-advisory-board/2480735/Nova Eye Medical has announced that Joe Bankovich, President of Nova Eye, has been appointed as an industry representative to the American Glaucoma Society Foundation Advisory Board. Established in 2011 and comprising over 1500 members, the American Glaucoma Society Foundation runs
- Hanita Lenses Launches Joint Venture with Ophthalmic Vision Care in the Iberian Peninsulahttps://modernod.com/news/hanita-lenses-launches-joint-venture-with-ophthalmic-vision-care-in-the-iberian-peninsula/2480732/Hanita Lenses announced a new joint venture with Madrid, Spain-based Ophthalmic Vision Care (OVC), a distributor IOLs for Hanita Lenses in Spain since 2016. The joint venture, named "Hanita Iberica," merges the assets of OVC—as a service provider of d
- Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI Surgical System in Pseudophakic Eyes with Open-Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-first-patient-treated-in-trident-european-trial-to-evaluate-the-omni-surgical-system-in-pseudophakic-eyes-with-open-angle-glaucoma/2480722/Sight Sciences announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent inject (Glaukos), in
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officerhttps://modernod.com/news/aerie-pharmaceuticals-appoints-peter-lang-as-chief-financial-officer/2480707/Aerie Pharmaceuticals announced that Peter F. Lang will join the company as Chief Financial Officer, effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals, and become a member of the Aerie Executive Committee.
- Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)https://modernod.com/news/kiora-pharmaceuticals-granted-orphan-drug-designation-for-kio-301-an-investigational-drug-for-the-treatment-of-retinitis-pigmentosa-rp/2480706/Kiora Pharmaceuticals has received orphan drug designation from the FDA for its investigational treatment of retinitis pigmentosa, KIO-301. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022. Orphan drug designation provides for facilitated development discussions with the FDA,
- Bunkers That Save Sight? UConn Researchers Take a Close Lookhttps://modernod.com/news/bunkers-that-save-sight-uconn-researchers-take-a-close-look/2480693/Chronically stressing the retina can weaken it and damage our ability to see. But retinal cells have a remarkable ability to wall off damage, a team of neuroscientists led by UConn Health reports in the 1 March issue of PNAS. The w
- Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis/2480680/Ocuphire Pharma announced that it has completed enrollment in the MIRA-4 trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis (RM) in 23 pediatric subjects. Ocuphire worked closely with Oculos Develop